The government has been focused on the biotechnology industry since 1984, when it set up a biotechnology and pharmaceutical industry development promotion task force. In 2007, it passed the Act for the Development of Biotech and New Pharmaceuticals Industry (生技新藥產業發展條例), and following the outbreak of the COVID-19 pandemic last year, the biotech industry has garnered even more attention.
FAILED PROGRAMS
However, a look at the “two trillion, twin star” program in 2002, the “six key emerging industries” program in 2009, the “5+2 industrial innovation” program in 2016 and last year’s “six core strategic industries” program shows that there has been progress in the industry, but not as much as expected.
The industry has not driven economic development in the same way that the semiconductor industry did, and insufficient international integration has failed to produce world-class companies or unicorns and it cannot compare with South Korea’s beauty and biotech OEM industries.
The value of Taiwan’s biotech industry is less than NT$600 billion (US$21.39 million), and it has only created about 100,000 job opportunities. There are several reasons for the limited results over the past four decades.
First, Taiwan’s social welfare environment and regulations are not conducive to the industry’s development, as healthcare is based on a non-profit policy. This is different from the semiconductor and other industries, which are mainly for-profit.
Second, many biotech firms had insufficient revenue and profit, but chose to list as “category 3 stocks” (now classified as tech stocks). They used publicity and speculation to attract funds from capital markets, while the government provided incentives in the form of rent and tax subsidies.
The result is that some biotech firms took shortcuts and speculated in stock. Moreover, a lack of capital and research and development talent made wide-scale human testing difficult, while insufficient international integration made building a complete supply chain a challenge.
Third, a lack of understanding of foreign pharmaceutical companies, difficulties obtaining information, incomplete understanding of regulations in other countries, differences in interpretation of provisions and disputes over agency or cooperation contracts often resulted in losses for local pharmaceutical and biotech companies that intend to enter the international market. Worse still, the authorities overseeing stock exchanges did not verify unclear information from other countries and imposed severe penalties, making matters worse.
VITAL ISSUES
The biotech industry faces many challenges. How can regulations be relaxed for the industry to facilitate cooperation with the high-tech industry, academics, development institutions and the medical sector? How will it raise capital, cultivate talent, create a complete supply chain and become a functional industry developing high-end biotech medicine and health and medical equipment? How will it tap into the distinct characteristics of individual markets to venture into the international market? How will it do these things with the support of the government and fair treatment from regulators, thus creating a new benchmark industry?
These are important issues that must be addressed by the industrial, government, academic, research and healthcare sectors.
Lee Shen-yi is a national policy adviser and vice chairman of the Contemporary Taiwan Development Foundation.
Translated by Perry Svensson
Elbridge Colby, America’s Under Secretary of Defense for Policy, is the most influential voice on defense strategy in the Second Trump Administration. For insight into his thinking, one could do no better than read his thoughts on the defense of Taiwan which he gathered in a book he wrote in 2021. The Strategy of Denial, is his contemplation of China’s rising hegemony in Asia and on how to deter China from invading Taiwan. Allowing China to absorb Taiwan, he wrote, would open the entire Indo-Pacific region to Chinese preeminence and result in a power transition that would place America’s prosperity
A few weeks ago in Kaohsiung, tech mogul turned political pundit Robert Tsao (曹興誠) joined Western Washington University professor Chen Shih-fen (陳時奮) for a public forum in support of Taiwan’s recall campaign. Kaohsiung, already the most Taiwanese independence-minded city in Taiwan, was not in need of a recall. So Chen took a different approach: He made the case that unification with China would be too expensive to work. The argument was unusual. Most of the time, we hear that Taiwan should remain free out of respect for democracy and self-determination, but cost? That is not part of the usual script, and
All 24 Chinese Nationalist Party (KMT) lawmakers and suspended Hsinchu Mayor Ann Kao (高虹安), formerly of the Taiwan People’s Party (TPP), survived recall elections against them on Saturday, in a massive loss to the unprecedented mass recall movement, as well as to the ruling Democratic Progressive Party (DPP) that backed it. The outcome has surprised many, as most analysts expected that at least a few legislators would be ousted. Over the past few months, dedicated and passionate civic groups gathered more than 1 million signatures to recall KMT lawmakers, an extraordinary achievement that many believed would be enough to remove at
Behind the gloating, the Chinese Nationalist Party (KMT) must be letting out a big sigh of relief. Its powerful party machine saved the day, but it took that much effort just to survive a challenge mounted by a humble group of active citizens, and in areas where the KMT is historically strong. On the other hand, the Democratic Progressive Party (DPP) must now realize how toxic a brand it has become to many voters. The campaigners’ amateurism is what made them feel valid and authentic, but when the DPP belatedly inserted itself into the campaign, it did more harm than good. The
RSS